Skip to content

MDMA-Assisted Psychotherapy for PTSD

Martim Marinheira Dias Sampaio Monteiro

Portuguese National Funding Agency for Science, Research and Technology July 1, 2019 DOI: 10.34626/28pn-xw25 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Review Peer reviewed
Population Patients with posttraumatic stress disorder (Phase 2 clinical trials reviewed)
Intervention MDMA-assisted psychotherapy
Topics MDMA Psychedelic-assisted therapy PTSD
Key findings The review reports that Phase 2 trials of MDMA-assisted psychotherapy for PTSD found significantly better outcomes for MDMA-exposed subjects than placebo-exposed cases in all but one study, with generally safe use in controlled settings and only one potential serious adverse effect ever reported. The authors argue the approach is appealing but requires further study before full approval.

Abstract

Background: Posttraumatic stress disorder is a mental illness with severe implications on patient quality of life and current treatment options, which are mainly psychotherapeutic, have limited results.Recently, MDMA, a highly controversial psychedelic drug, has shown promise as a psychotherapeutic enhancer.Objective: This review aims to outline existing scientific evidence on the efficacy of MDMA-assisted psychotherapy in treating posttraumatic stress disorder.Other important theoretical knowledge and empirical evidence regarding the drug will also be presented.Method: Using PubMed as the database, a research was conducted targeting articles written in English about MDMA's use in posttraumatic stress disorder's treatment.Results: MDMA is still a drug whose complete means of action, albeit known to be mostly related with neurotransmitter metabolism, is not fully understood.Mechanisms involving mood, empathy and arousal modulation, as well as neuroplasticity and long-term personality changes have been proposed as the reason for its properties as a good psychotherapeutic catalyst, but the true explanation remains a matter of scientific debate.Phase 2 clinical trials in patients suffering with posttraumatic stress disorder have so far delivered very promising

Results: MDMA exposed subjects have shown significantly better results when compared to placebo exposed cases in all but one study, and its application in controlled settings has been considered generally safe, with only one potential serious adverse effect ever reported.Phase 3 clinical trials have been justifiably approved and should address issues regarding the direct comparison with the current preconized treatment options, the optimization of the adverse effects profile, and the reproducibility of the results.Conclusion: MDMA-assisted psychotherapy is a very appealing new possibility in the treatment of posttraumatic stress disorder.Future studies are necessary for it to become a fully approved therapy.

Comparable studies

Other narrative reviews on MDMA and psychedelic-assisted therapy, most cited first.

Explore topics

By condition and practice